Molybdocen-dichlorid als Antitumor-Agens / Molybdocene Dichloride as an Antitumor Agent

Abstract
The antitumor activity of molybdocene dichloride is tested against Ehrlich ascites tumor in CF1 mice. The application of 75 or 100 mg/kg 24 h after transplantation achieves 100% tumor inhibi­tion until day 30. Following the d0 and d1 metallocene dichlorides of titanium and vanadium, molybdocene dichloride is the First analogous d2 system revealing similar antineoplastic properties.

This publication has 0 references indexed in Scilit: